MAYO CLINIC LABORATORIES

1-800-533-1710

BALAF

B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult, Varies

Patient ID	Patient Name		Birth Date	Gender	Age
SA00148985	TESTINGRNV, BALAF-ABNORMAL		1965-10-29	M	55
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00148985	SA00148985	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		14 Oct 2021 06:16			

Adult ALL (B-cell), FISH

Result Summary

MCR

Abnormal

Interpretation

MCR

The result is abnormal and indicates 75% of nuclei had BCR/ABL1 fusion. This result should be correlated with a conventional chromosome study.

BCR/ABL1 fusion has been associated with an unfavorable prognosis in B-lymphoblastic leukemia/lymphoma (B- ALL). However, outcomes associated with this rearrangement appear to be more favorable with the advent of targeted tyrosine kinase inhibitors. Clinical and pathologic correlation is recommended (Iacobucci et al., J Clin Oncol 35:975–983, 2017; Roberts et al., Nat Rev Clin Onc 12:344–357, 2015).

For monitoring response to therapy, RT-PCR for BCR/ABL1 is recommended, per NCCN guidelines. Although RT-PCR testing is not available on the current specimen, this testing can be performed on blood or bone marrow collected in EDTA or ACD. Please call 800–533–1710 regarding specimen requirements for RT-PCR based tests.

Result Table

MCR

Abnormality Name	Result	Abn%	Cutoff%
t(9;22) ABL1/BCR fusion	Abnormal	75	<4.0
t(XorY;14) CRLF2/IGH fusion	Normal		<4.0

Result

MCR

nuc ish(ABL1,BCR)x3(ABL1 con BCRx2)[150/200]

Reason for Referral

MCR

Leukocytosis

Specimen

MCR

Bone Marrow

Source

MCR

Left posterior iliac crest

Method

MCR

Locus and probes	[Strategy;#Nuclei;Class]
9q34(ABL1), 22q11.2(BCR)	[DFISH;200;AM]
Xp22.33/Yp11.32(CRLF2), 14q32(IGH)	[DFISH;200;LDT]

Probe strategies include:
DFISH=dual color, double fusion.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AM = Abbott Molecular, Inc (Des Plaines, IL)

Disclaimer

MCR

Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Released By

MCR

Jess F. Peterson, M.D.

Received: 15 Oct 2021 07:22 **Reported:** 25 Oct 2021 10:23

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292